BUDGET IMPACT MODEL OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF COPD IN ITALY BASED ON FLAME STUDY
Author(s)
Pitotti C1, Burke C2, Sanyal R3, Aiello A4
1Novartis Farma, Origgio, Italy, 2Product Lifecycle Services - Novartis Business Services, Dublin, Ireland, 3Novartis Healthcare Pvt. Ltd, Hyderabad, Telangana, India, 4Creativ Ceutical, Milan, Italy
OBJECTIVES: A 3-year budget-impact model (BIM) using data from the FLAME study was developed to estimate the economic impact on the Italian health care budget of switching COPD patients treated with salmeterol/fluticasone to indacaterol/glycopyrronium. METHODS: The model considered patients with moderate, severe and very severe COPD who are diagnosed and treated only with salmeterol/fluticasone or indacaterol/glycopyrronium in the Italian setting. The BIM was developed from the perspective of the National Healthcare Service (NHS). Only direct medical costs were considered: drug costs (salmeterol/fluticasone and indacaterol/glycopyrronium ), adverse events costs (pneumonia, tuberculosis and influenza) and disease-related costs (exacerbations management costs, emergency department and hospitalisation). The model assumes an uptake of patients treated with indacaterol/glycopyrronium of 50% in the first year, 30% in the second year and 30% in the third year deriving from salmeterol/fluticasone. Public net prices and National Tariffs were considered to estimate cost of drugs and medical resources used, respectively. Costs were assessed in Euros (2015). RESULTS: The total number of patients considered in the model was 195.518 (Year 1), 4.100 of which treated with indacaterol/glycopyrronium. After switching, the number of patient treated with indacaterol/glycopyrronium was estimated to be 151.865 (at Year 3). The reduction of exacerbation events (moderate, severe and very severe) was estimated to be 28.852. Considering all costs, as listed, the budget impact of switching patients from salmeterol/fluticasone to indacaterol/glycopyrronium was estimated to generate a saving of 10 million Euros over 3 years for the NHS. Considering only drugs costs, it was estimated saving would be CONCLUSIONS: Indacaterol/glycopyrronium compared to salmeterol/fluticasone used to treat moderate, severe and very severe COPD patients was estimated to be cost saving for the Italian NHS. Greater savings are predicted if a higher number of patients switch to indacaterol/glycopyrronium.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PRS9
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Respiratory-Related Disorders